novo nordisk

novo nordisk will continue offering its top-selling insulin brand, Mixtard, in vial form in India, despite phasing out Penfill cartridges. This decision follows concerns about the discontinuation of widely used insulin products. The company aims to consolidate its insulin portfolio to meet increasing patient demand and ensure a stable medicine supply, focusing on newer treatments.

Ozempic, originally for type 2 diabetes, has surged in popularity in North America as a weight-loss solution, sparking a cultural and medical shift. Its off-label use, fueled by celebrity endorsements and social media trends, has led to increased demand and supply shortages. While effective, Ozempic's health risks, regulatory challenges, and cultural impact are under scrutiny.

Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable drugs like Ozempic

A recent Italian study reveals Mounjaro's effectiveness in maintaining weight loss over three years, particularly benefiting women. Participants using tirzepatide, the active ingredient in Mounjaro, experienced a 30% body weight reduction compared to 10% in the placebo group. Women demonstrated greater and more sustained weight loss, highlighting the drug's potential for long-term weight management.

Eli Lilly's experimental oral pill, orforglipron, has shown promising results in Phase 3 trials, effectively lowering weight and blood sugar levels similar to Ozempic in diabetes patients. This once-daily pill offers a convenient, alternative to blockbuster drugs like Ozempic. With potential regulatory approvals expected by year-end, orforglipron could significantly transform the weight-loss drug market.

SAP has become Europe's largest company by market capitalisation, surpassing novo nordisk. Increased optimism in its cloud business and the growing investments in generative artificial intelligence contributed to this rise. novo nordisk, previously Europe's most valuable company, saw a downturn due to disappointing trial data for its new obesity drug.

Eli Lilly plans to turn India into a growth market by addressing its diabetes and obesity challenges with its new treatment, Mounjaro. CEO David Ricks is optimistic about India's growth potential and highlights the transformative power of innovative medicines alongside generics in managing public health.

Pharma giant Eli Lilly has launched Mounjaro, a popular weight-loss drug, in India. Priced at Rs 3,500 for 2.5 mg and Rs 4,375 for 5 mg, Mounjaro is available by prescription and aims to address obesity and type 2 diabetes. The tirzepatide shortage has been resolved.

Mounjaro (tirzepatide) is an FDA-approved antidiabetic injection gaining popularity for its effectiveness in weight management and diabetes treatment. Offering a dual-action mechanism targeting GLP-1 and GIP receptors, it has shown potential benefits over Ozempic and is now available in India at a significantly lower cost.

Eli Lilly has launched Mounjaro in India, a new once-weekly injectable drug for type 2 diabetes and weight management. Approved by CDSCO, it targets GIP and GLP-1 receptors, aiming to improve blood sugar control and aid in weight loss. Clinical trials showed significant results, underlining its potential in treating diabetes and obesity.

The United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) reports an increase in deaths linked to weight loss and diabetes drugs, including Mounjaro, Wegovy, and Ozempic. By January 2025, adverse reactions had resulted in 22 fatalities. Medical professionals stress the need for careful prescription and supervision to mitigate risks.

Even five months after the announcement by health minister Laxmikant Parsekar in the assembly that government will review its agreement with novo nordisk, Goa medical college (GMC) continues to purchase insulin injections from the same company.

BANGALORE: novo nordisk Pharma India, the Indian subsidiary of Danish pharma major novo nordisk, has refuted allegations that the clinical trials of ragaglitazar, an insulin sensitiser used for the treatment of Type II diabetes, were conducted in an unethical manner.

HCL Technologies (HCL) has won a contract from Danish pharma major novo nordisk to provide global service desk and on-site support. HCL will help novo nordisk transform its IT operations and create world-class end-user experiences and drive efficiency across its workforce.

HYDERABAD: novo nordisk, a global drug major, has decided to dump the insulin sensitiser compound Ragaglitazar developed by the city-based Dr Reddy’s Laboratories. With this decision, all the activities to develop the compound will come to a halt.

HYDERABAD: novo nordisk has decided to dump the insulin sensitiser compound Ragaglitazar developed by the city-based pharma major Dr Reddy's Laboratories (DRL). With this decision, all the activities that are in the pipeline to develop the compound will come to a halt.

NEW DELHI: Dr Reddy’s Laboratories on Monday said that cancellation of agreement between Novartis Pharma and novo nordisk to commercialise dual-acting insulin sensitiser for the treatment of Type 2 diabetes, would not affect the development of the drug.